Continuous Subcutaneous Foslevodopa/Foscarbidopa Improves Nonmotor Symptoms and Fluctuations in Parkinson's Disease
- 1Department of Advanced Medical and Surgical Sciences University of Campania “Luigi Vanvitelli” Napoli Italy
- 2Department of Psychology University of Campania “Luigi Vanvitelli” Caserta Italy
Abstract
Background: Nonmotor fluctuations (NMFs) in Parkinson's disease (PD) represent a heterogeneous and disabling feature often linked to pulsatile dopaminergic stimulation from oral levodopa. Continuous subcutaneous foslevodopa/foscarbidopa infusion (CSFLI) provides 24‐h levodopa delivery, with established motor benefits but limited real‐world data on NMFs. We investigated changes in motor complications, nonmotor symptoms, and NMFs over 3 months after initiation of CSFLI.
Methods: In this prospective, single‐center, real‐world study, 66 patients with advanced PD initiated CSFLI. Longitudinal 3‐month data were available for 40 patients. Motor complications were assessed with the Unified Parkinson's Disease Rating Scale (UPDRS) Part IV, motor severity with UPDRS Part III, and nonmotor symptoms with the Nonmotor Symptom Scale (NMSS); nonmotor fluctuations were evaluated with the Nonmotor Fluctuation Assessment questionnaire (NoMoFa). Additional validated scales assessed sleep, mood, fatigue, autonomic, and behavioral symptoms. Longitudinal changes were analyzed using paired parametric or non‐parametric tests, as appropriate, with FDR correction.
Results: After 3 months, motor complications significantly improved, with reductions in OFF time and ON time with dyskinesias. Nonmotor symptom burden also improved, with significant reductions in NoMoFa total and NMF‐OFF scores, whereas NMF‐ON remained unchanged. Improvements were also observed in sleep‐related symptoms, depressive symptoms, and quality of life, whereas apathy, autonomic symptoms, and daytime sleepiness did not significantly change.
Conclusions: CSFLI was associated with improvements in motor complications and nonmotor fluctuations, particularly OFF‐related NMFs, together with benefits in specific nonmotor symptoms. These findings provide preliminary real‐world evidence supporting a potential role of CSFLI in the management of NMFs in PD.
Related
- Ekbom Spectrum Psychosis Associated with 24-hour Continuous Subcutaneous Foslevodopa/Foscarbidopa Infusion in Parkinson’s Disease
- Alkaline Phosphatases: A Potential Cause of Variability in Therapeutic Response to Continuous Subcutaneous Foslevodopa/Foscarbidopa Infusion?
- Homocysteine as a Key Biomarker of Metabolic Stress During Foslevodopa/Foscarbidopa Infusion Therapy
- Long-term safety profile of opicapone in patients with Parkinson’s disease and early fluctuations
- Pneumomediastinum and Subcutaneous Emphysema After Rapid Mediastinal Mass Regression
BibTeX
@article{micco2026continuous,
title = {{Continuous Subcutaneous Foslevodopa/Foscarbidopa Improves Nonmotor Symptoms and Fluctuations in Parkinson's Disease}},
author = {Rosa De Micco and Oriana Ciaramaglia and Mattia Siciliano and Valeria Sant'Elia and Claudio Cabato and Ferdinando Ambrosio and Alessandro Tessitore},
journal = {European Journal of Neurology},
year = {2026},
month = oct,
doi = {10.1111/ene.70788},
url = {https://doi.org/10.1111/ene.70788},
note = {CC BY-NC 4.0},
}
RIS
TY - JOUR
TI - Continuous Subcutaneous Foslevodopa/Foscarbidopa Improves Nonmotor Symptoms and Fluctuations in Parkinson's Disease
AU - Rosa De Micco
AU - Oriana Ciaramaglia
AU - Mattia Siciliano
AU - Valeria Sant'Elia
AU - Claudio Cabato
AU - Ferdinando Ambrosio
AU - Alessandro Tessitore
PY - 2026
DA - 2026/10/01
JO - European Journal of Neurology
DO - 10.1111/ene.70788
UR - https://doi.org/10.1111/ene.70788
AB - Background: Nonmotor fluctuations (NMFs) in Parkinson's disease (PD) represent a heterogeneous and disabling feature often linked to pulsatile dopaminergic stimulation from oral levodopa. Continuous subcutaneous foslevodopa/foscarbidopa infusion (CSFLI) provides 24‐h levodopa delivery, with established motor benefits but limited real‐world data on NMFs. We investigated changes in motor complications, nonmotor symptoms, and NMFs over 3 months after initiation of CSFLI. Methods: In this prospective, single‐center, real‐world study, 66 patients with advanced PD initiated CSFLI. Longitudinal 3‐month data were available for 40 patients. Motor complications were assessed with the Unified Parkinson's Disease Rating Scale (UPDRS) Part IV, motor severity with UPDRS Part III, and nonmotor symptoms with the Nonmotor Symptom Scale (NMSS); nonmotor fluctuations were evaluated with the Nonmotor Fluctuation Assessment questionnaire (NoMoFa). Additional validated scales assessed sleep, mood, fatigue, autonomic, and behavioral symptoms. Longitudinal changes were analyzed using paired parametric or non‐parametric tests, as appropriate, with FDR correction. Results: After 3 months, motor complications significantly improved, with reductions in OFF time and ON time with dyskinesias. Nonmotor symptom burden also improved, with significant reductions in NoMoFa total and NMF‐OFF scores, whereas NMF‐ON remained unchanged. Improvements were also observed in sleep‐related symptoms, depressive symptoms, and quality of life, whereas apathy, autonomic symptoms, and daytime sleepiness did not significantly change. Conclusions: CSFLI was associated with improvements in motor complications and nonmotor fluctuations, particularly OFF‐related NMFs, together with benefits in specific nonmotor symptoms. These findings provide preliminary real‐world evidence supporting a potential role of CSFLI in the management of NMFs in PD.
SN - 1351-5101
SN - 1468-1331
ER -